Genmab A/S (NASDAQ:GMAB) Shares Gap Down - What's Next?

Genmab A/S (NASDAQ:GMAB - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $19.76, but opened at $19.01. Genmab A/S shares last traded at $19.09, with a volume of 178,264 shares trading hands.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. HC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Truist Financial lowered their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research report on Thursday, February 13th. Finally, William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Genmab A/S currently has an average rating of "Moderate Buy" and a consensus price target of $41.33.

Genmab A/S Trading Down 1.5 %

The company's 50-day moving average is $20.91 and its 200 day moving average is $21.97. The firm has a market cap of $13.13 billion, a PE ratio of 11.41, a P/E/G ratio of 2.65 and a beta of 0.98.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, research analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

Institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of Genmab A/S by 94.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company's stock valued at $636,000 after buying an additional 12,654 shares during the last quarter. Cerity Partners LLC lifted its stake in shares of Genmab A/S by 14.6% in the 3rd quarter. Cerity Partners LLC now owns 48,003 shares of the company's stock valued at $1,170,000 after purchasing an additional 6,103 shares during the last quarter. FMR LLC boosted its holdings in Genmab A/S by 13.5% in the third quarter. FMR LLC now owns 278,194 shares of the company's stock worth $6,782,000 after purchasing an additional 33,076 shares in the last quarter. Verition Fund Management LLC acquired a new position in shares of Genmab A/S during the 3rd quarter valued at about $709,000. Finally, HighTower Advisors LLC acquired a new position in shares of Genmab A/S during the 3rd quarter valued at about $273,000. Institutional investors and hedge funds own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.